Article Sidebar

Submitted
April 28, 2024
Accepted
April 28, 2024
Published
April 28, 2024
Download
PDF
Statistic
Read Counter : 319 Download : 240

Main Article Content

Abstract

Background: growth of microorganisms on heart valves inner lining eventually cause what is called infective
endocarditis. The pathological core lesion of infective endocarditis is termed a vegetation, which is composed
of colonies of microorganisms, inflammatory cells, fibrin and platelets.
Aims: to clarify the clinical background, microbiological entity and in hospital course of patients with
infective endocarditis in Ibn-AL Betar cardiac Centre.
Methods: all patients with infective endocarditis admitted to Ibn-AL Betar cardiac center between June 2018
and January 2020 were studied. Echocardiography and lab tests done for all patients. Pregnant women and
pediatrics less than 14 years old were excluded from the study.
Results: our studied group was 30 patients, 30% female and 70% male with a median age of 34 years.
Infective endocarditis affecting native valves in 20 patients (66.6%), prosthetic valves in 5 patients (16.6%),
associating congenital heart disease in 4 patients (16.6%) and device related in one patient (3.3%). most
common valve to be infected was the aortic valve. Blood culture was positive in 8 patients
(26.6%).Staphylococcus aureus were the prevalent microorganism (16.6%).In hospital complications included:
heart failure in 22 patients (73.3%), septic shock in 5 patients (16.6%), acute renal failure in 4 patients
(13.3%), paravalvular abscess in 2 patients (6.6%), systemic embolization in 2 patients (6.6%) and septic
pulmonary embolization in 2 patients (6.6%). Surgery is indicated in 14 patients (46.6%); of them 5 patients
(16.6%) undergoing early surgical intervention. In hospital mortality was (16.6%).
Conclusion :Infective endocarditis is a hazardous disease. It comprises an increase in-hospital complications
with an enhanced mortality rate (16.6%). Staphylococcus aureus are the prevalent microorganism. Fever and
dyspnea are commonest presentations while peripheral stigmata of endocarditis were rarely observed in our
study.

Article Details

License

Copyright (c) 2024 University of Thi-Qar Journal Of Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. D. T. Durack, A. S. Lukes, D. K. Bright et al., “New criteria for diagnosis of infective
  2. endocarditis: utilization of specific echocardiographic findings,” The American Journal
  3. ofMedicine, vol. 96, no. 2, pp. 200–209, 1994
  4. Correa de Sa DD, Tleyjeh IM, Anavekar NS, et al. Epidemiological trends of infective
  5. endocarditis: a population-based study in Olmsted County, Minnesota. Mayo Clin Proc 2010;
  6. :422-6. [Erratum, Mayo Clin Proc 2010; 85:772.]
  7. Duval X, Delahaye F, Alla F, et al.Temporal trends in infective endocarditis in the context of
  8. prophylaxis guideline modifications: three successive population-
  9. based surveys. J Am Coll Cardiol 2012; 59:1968-76.
  10. Fedeli U, Schievano E, Buonfrate D, Pellizzer G, Spolaore P. Increasing incidence and
  11. mortality of infective endocarditis: a population-based study through a
  12. record-linkage system. BMC Infect Dis 2011; 11:48.
  13. Federspiel JJ, Stearns SC, Peppercorn AF, Chu VH, Fowler VG Jr. Increasing US rates of
  14. endocarditis with Staphylococcus aureus: 1999-2008. Arch Intern Med 2012; 172:363-5.
  15. Sy RW, Kritharides L. Health care exposure and age in infective endocarditis: results of a
  16. contemporary population based profile of 1536 patients in Australia.
  17. Eur Heart J 2010; 31:1890-7.
  18. Murdoch DR, Corey GR, Hoen B, et al.Clinical presentation, etiology, and outcome of
  19. infective endocarditis in the 21stcentury: the International Collaboration on EndocarditisProspective Cohort Study.
  20. Arch Intern Med 2009; 169:463-73.
  21. Selton-Suty C, Célard M, Le Moing V,
  22. et al. Preeminence of Staphylococcus aureus
  23. in infective endocarditis: a 1-yearpopulation-based survey. Clin Infect Dis 2012; 54:1230-9.
  24. Tleyjeh IM, Abdel-Latif A, Rahbi H, et al. A systematic review of populationbased studies of
  25. infective endocarditis. Chest 2007; 132:1025-35.
  26. Fournier PE, Thuny F, Richet H, et al.Comprehensive diagnostic strategy for blood culturenegative endocarditis: a prospective study of 819 new cases. Clin
  27. Infect Dis 2010; 51:131-40.
  28. Houpikian P, Raoult D. Blood culturenegative
  29. endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005;
  30. :162-73.
  31. Stehbens WE, Delahunt B, Zuccollo JM. The histopathology of endocardial sclerosis.
  32. Cardiovasc Pathol 2000; 9:161-73.
  33. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. Clin Microbiol Rev
  34. ; 14:177-207.
  35. Li JS, Sexton DJ, Mick N, et al. Propose modifications to the Duke criteria for the diagnosis
  36. of infective endocarditis. Clin Infect Dis 2000; 30:633-8.
  37. Greub G, Lepidi H, Rovery C, et al. Diagnosis of infectious endocarditis in patients
  38. undergoing valve surgery. Am J Med 2005; 118:230-8.
  39. Lepidi H, Coulibaly B, Casalta JP, Raoult D. Autoimmunohistochemistry: a new method for
  40. the histologic diagnosis of infective endocarditis. J Infect Dis
  41. ; 193:1711-7.
  42. Botelho-Nevers E, Thuny F, Casalta JP, et al. Dramatic reduction in infective endocarditisrelated mortality with a management- based approach. Arch Intern Med 2009; 169:1290-8.
  43. Morris AJ, Drinković D, Pottumarthy S, MacCulloch D, Kerr AR, West T. Bacteriological
  44. outcome after valve surgery for active infective endocarditis: implications
  45. for duration of treatment after surgery. Clin Infect Dis 2005; 41:187-94.
  46. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of
  47. infective endocarditis (new version 2009): the Task Force on the
  48. Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of
  49. Cardiology (ESC): endorsed by the European Society of Clinical Microbiology and Infectious
  50. Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and
  51. Cancer. Eur Heart J 2009; 30:2369-413.
  52. R. S. Math, G. Sharma, S. S. Kothari et al., “Prospective study of infective endocarditis from
  53. a developing country,” TheAmerican Heart Journal, vol. 162, no. 4, pp. 633–638, 2011.
  54. S. S. Kothari, S. Ramakrishnan, andV. K. Bahl, “Infective endocarditis—an Indian
  55. perspective,” Indian Heart Journal, vol. 57, no. 4, pp. 289–294, 2005.
  56. N.Garg, B. Kandpal, S. Tewari,A.Kapoor, P. Goel, andN. Sinha, “Characteristics of infective
  57. endocarditis in a developing country- clinical profile and outcome in 192 Indian patients, 1992–
  58. ,” International Journal of Cardiology, vol. 98, no. 2, pp. 253–260, 2005.
  59. Hill EE, Herijgers P, Claus P, et al. Infective endocarditis: changing epidemiology and
  60. predictors of 6-month mortality: a prospective cohort study. Eur Heart J 2007; 28:196.
  61. Al-Mogheer B, Ammar W, Bakoum S, et al. Predictors of inhospital mortality in patients
  62. with infective endocarditis. The Egypt Heart J 2012. Article in press.
  63. Murdoch DR, Corey GR, Hoen BL. Clinical presentation, etiology, and outcome of infective
  64. endocarditis in the 21st century. Arch Intern Med. 2009; 169:463.
  65. Chaudhary R. Active infective endocarditis observed in an Indian Hospital 1981-91. Am J
  66. Cardiol. 1992; 70:1453-8.
  67. Baddour LM, Wilson WR, Bayer AS. Infective endocarditis: Diagnosis, antimicrobial
  68. therapy, and management of complications. A statement for healthcare professionals from the
  69. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on
  70. Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and
  71. Cardiovascular Surgery and Anesthesia, American HeartAssociation. Circulation. 2005;
  72. :e394.
  73. Kabde VR, Bidwai PS, Berry JN, Agarwal KC. Clinical and bacteriological studies in
  74. infective endocarditis. Indian Heart J. 1970; 22:318-32.
  75. Agarwal RK, Gupta R, Agarwal SC, Dwivedi M. Bacterial endocarditis-its diagnostic
  76. problems. J Assoc Physicians India. 1981; 29:745-50.
  77. Bayer AS, Bolger AF, Taubert KA. Diagnosis and management of infective endocarditis and
  78. its complications. Circulation. 1998; 98:2936.
  79. Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a
  80. -year survey in France. JAMA 2002; 288:75–81.
  81. Yiu KH, Siu CW, Lee KL, Fong YT, et al. Emerging trends of community acquired infective
  82. endocarditis. Int J Cardiol 2007; 121: 119–22.
  83. Rivas P, Alonso J, Moya J, et al. The impact of hospital-acquired infections on the microbial
  84. etiology and prognosis of late-onset prosthetic valve endocarditis. Chest 2005; 128:764–71.
  85. Tariq M, Karim B. Int J Collaborative Res Intern Med Public Health 2009; 1(3):84–99.
  86. Yousuf RM, How SH, Fauzi ARM, et al. Infective endocarditisin the east coast of peninsula
  87. Malaysia: a two year retrospectivesurvey from Kuantan. JK-Practitioner 2006; 13(1):5–8.
  88. Steckelberg JM, Wilson WR. Risk factors for infective endocarditis. Infect Dis Clin North
  89. Am 1993; 7:9–19.
  90. Klug D, Balde M, Pavin D, Hidden-Lucet F, et al. Risk factors related to infections of implanted
  91. pacemakers and cardioverterdefibrillators: results of a large prospective study. Circulation 2007;
  92. :1349–55.
  93. Rehman S, Ghulam Shabbier, Shahid M. Clinical presentation of infective endocarditis. J Postgrad
  94. Med Inst 2002; 16: 55–63.
  95. Chen CH, Lo MC, Hwang KL, et al. Infective endocarditis with neurological complication: 10 year
  96. experience. J Mcrobiol Immunol Infect 2001; 34:119–24.
  97. Zamorano J, Sanz J, Almeria C, et al. Difference betweenendocarditis with true negative blood
  98. cultures and those withprevious antibiotic treatment. J Heart valve Dis 2003; 12:256–60.
  99. Mylonakis E, Calderwood SB. Infective endocarditis in adults. NEngl J Med 2001; 345:1318–30.
  100. C. Rostagno, G. Rosso, F. Puggelli et al., “Active infective endocarditis:clinical characteristics and
  101. factors related to hospitalmortality,” Cardiology Journal, vol. 17, no. 6, pp. 566–573, 2010.
  102. J. C. Castillo, M. P. Anguita, M. Ruiz et al., “Changing epidemiologyof native valve infective
  103. endocarditis,” Revista Espanola deCardiologia, vol. 64, no. 7, pp. 594–598, 2011.
  104. Kini V, Logani S, Ky B. Transthoracic and transesophageal echocardiography for the indication of
  105. suspected infective endocarditis: Vegetations, blood cultures and imaging. J Am Soc Echocardiograph.
  106. ; 23:396.
  107. Tornos P, Iung B, Permanyer-Miralda G, et al. Infective endocarditisin Europe: lessons from the Euro
  108. heart survey. Heart2005; 91:571–5.
  109. Van Le, Gill S. Serious complications after infective endocarditis.Dan Med Bul 2010; 57(10).
  110. Habib G. Management of infective endocarditis. Heart
  111. ; 92:124–30.
  112. Nashmi A, Memish ZA. Infective endocarditis at a tertiary carecentre in Saudi Arabia: review of 47
  113. cases over 10 years. EastMediterr Health J 2007; 13:64–71.
  114. Erbay AR, Erbay A, Canga A, et al. Risk factors for in-hospitalmortality in infective endocarditis: five
  115. years’ experience at a tertiary care hospital in Turkey. J Heart Valve Dis 2010; 19(2):216.
  116. Ruotsalainen E, Sammalkorpi K, et al. Clinical manifestationsand outcome in Staphylococcus aureus
  117. endocarditis amonginjection drug users and non addicts: a prospective study of 74patients. BMC Infect
  118. Dis 2006; 6:137.
  119. Miyake M, Hatta K, Kameyama T, et al. Infective endocarditisdeveloping as uremia. Intem Med
  120. ; 44:598–6